Analyst Ratings For NASDAQ:ADMA – ADMA Biologics (NASDAQ:ADMA)
Today, LADENBURG THALM/SH SH lowered its price target on NASDAQ:ADMA – ADMA Biologics (NASDAQ:ADMA) to per share.
Some recent analyst ratings include
- 11/14/2017-Raymond James Upgrade from a “Market Perform ➝ Outperform” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:ADMA – ADMA Biologics (NASDAQ:ADMA)
NASDAQ:ADMA – ADMA Biologics (NASDAQ:ADMA) has insider ownership of 16.90% and institutional ownership of 37.42%.
- On 6/8/2018 Adam S Grossman, CEO, bought 52,301 with an average share price of $4.78 per share and the total transaction amounting to $249,998.78.
- On 6/8/2018 Brian Lenz, CFO, bought 5,000 with an average share price of $4.78 per share and the total transaction amounting to $23,900.00.
- On 6/8/2018 Jerrold B Grossman, Director, bought 20,921 with an average share price of $4.78 per share and the total transaction amounting to $100,002.38.
- On 11/9/2017 Adam S Grossman, Insider, bought 485,000 with an average share price of $2.15 per share and the total transaction amounting to $1,042,750.00.
- On 11/9/2017 Brian Lenz, CFO, bought 6,500 with an average share price of $2.15 per share and the total transaction amounting to $13,975.00.
- On 11/9/2017 Eric I Richman, Director, bought 25,000 with an average share price of $2.15 per share and the total transaction amounting to $53,750.00.
- On 11/9/2017 James Mond, CMO, bought 10,000 with an average share price of $2.15 per share and the total transaction amounting to $21,500.00.
Recent Trading Activity for NASDAQ:ADMA – ADMA Biologics (NASDAQ:ADMA)
Shares of NASDAQ:ADMA – ADMA Biologics closed the previous trading session at 4.65 down -0.20 4.12% with 4.880000114440918 shares trading hands.